BKS Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

BKS Advisors’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$854K	Sell	15,395 -500	-3%	-$26.9K	0.34%	76
2018 Q4	$669K	Sell	15,895 -3,930	-20%	-$205K	0.3%	82
2018 Q3	$1.38M	Sell	19,825 -900	-4%	-$58.8K	0.51%	53
2018 Q2	$1.19M	Sell	20,725 -1,000	-5%	-$54.5K	0.42%	66
2018 Q1	$1.2M	Sell	21,725 -2,000	-8%	-$120K	0.44%	63
2017 Q4	$1.33M	Hold	23,725	–	–	0.48%	58
2017 Q3	$1.45M	Hold	23,725	–	–	0.56%	51
2017 Q2	$1.27M	Sell	23,725 -8,800	-27%	-$429K	0.52%	57
2017 Q1	$1.57M	Sell	32,525 -4,550	-12%	-$212K	0.69%	46
2016 Q4	$1.48M	Sell	37,075 -10,725	-22%	-$458K	0.7%	49
2016 Q3	$2.32M	Buy	47,800 +37,000	+343%	+$1.76M	1.07%	33
2016 Q2	$419K	Buy	10,800 +4,800	+80%	+$207K	0.22%	102
2016 Q1	$245K	Buy	+6,000	New	+$265K	0.13%	146

Other funds holding BIB

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BRC

Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SBIA

Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

CAL

Capital Analysts LLC Fort Washington, Pennsylvania $3.81B AUM 15.52% 1-Year Est. Return

BKS Advisors's BIB Position: Q1 2019 in Review

BKS Advisors reduced its ProShares Ultra NASDAQ Biotechnology (BIB) stake by 3.1% in Q1 2019, selling an estimated $26.9K and leaving 15,395 shares worth $854K. The position accounts for 0.34% of the portfolio, ranked #76.

BKS Advisors first reported a position in BIB in Q1 2016 and has held it in 13 quarters since. The position peaked at $2.32M in Q3 2016. 27 funds tracked by Wall St. Rank hold BIB as of Q1 2019.

BKS Advisors held 15,395 shares of ProShares Ultra NASDAQ Biotechnology worth $854K as of Q1 2019.
BKS Advisors sold 500 ProShares Ultra NASDAQ Biotechnology shares in Q1 2019, an estimated $26.9K.
ProShares Ultra NASDAQ Biotechnology made up 0.34% of BKS Advisors's portfolio in Q1 2019, its #76 holding.
BKS Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2016 and has held it in 13 quarters since.
BKS Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $2.32M in Q3 2016.
27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2019.

Based on BKS Advisors's 13F filing for Q1 2019, filed 16 Apr 2019.